ISA Pharmaceuticals

Company: Company highlights


  • ISA Pharmaceuticals appoints Gerard Platenburg as CEO. (March 2009)

  • A clinical trial with ISA's p53-SLP vaccine proves the induction of strong p53 specific immune responses in patients with metastatic colorectal cancer. (December 2008)

  • ISA-HPV-01 induces objective clinical responses in phase II trial with VIN III patients. (December 2008)

  • ISA Pharmaceuticals starts clinical Phase II trial with its ISA-p53 vaccine in combination with low-dose chemotherapy in patients with ovarian cancer. (October 2008)

  • ISA Pharmaceuticals starts randomized clinical Phase II trial with ISA-HPV-01 in patients with high grade VIN. (October 2008)

  • The first clinical trial with ISA's p53-SLP vaccine shows it is safe, well tolerated and that it induces strong p53-specific T-cell responses in ovarian cancer patients. (July 2008)

  • ISA Pharmaceuticals establishes collaboration with Ludwig Institute for Cancer Research (LICR). (July 2008)

  • ISA Pharmaceuticals finalizes third phase I clinical trial ISA-HPV-01 in patients with cervical carcinoma, all with different vaccination schedules. ISA-HPV-01 is well tolerated in this patient group, induces robust immune responses and shows promising clinical data. (January 2008)

  • Professor Cornelis Melief joins ISA Pharmaceuticals as CSO. (January 2008)

  • ISA Pharmaceuticals obtains grant from Top Institute Pharma (TIP) with consortium on "Exploitation of toll-like receptors in drug discovery" to strengthen its adjuvant technology platform. (November 2007)

  • ISA Pharmaceuticals obtains the Orphan Drug Designation in Europe for its SLP® vaccine against HPV16 for treatment of HPV positive Vulvar Intraepithelial Neoplasia (VIN) (November 2007)

  • ISA Pharmaceuticals obtains world-wide exclusive rights of the Dutch Vaccine Institute's spin-off company, ImSaVac B.V., regarding a proprietary class of vaccine adjuvants for the prevention and treatment of cancer. (October 2007)

  • ISA Pharmaceuticals initiates Phase I/II trial with ISA-HPV-01 in patients with CIN II/III. (April 2007)

  • ISA Pharmaceuticals initiates Phase I/II trial with ISA-HPV-01 in patients with Cervical Intraepithelial Neoplasia grade I (CIN I). (April 2007)

  • ISA Pharmaceuticals names Johan Frieling as CMO. (January 2007)

  • Prof. Melief wins the Dutch price "Prijs van Wetenschap en Maatschappij" (Price for Science and Society) for his seminal contribution in the development of a Therapeutic vaccine against HPV. (November 2006)

  • ISA Pharmaceuticals initiates collaboration with the University Medical Center Groningen (UMCG) regarding the clinical development of its ISA-p53 vaccine in patients with ovarian cancer. (July 2006)

  • ISA Pharmaceuticals obtains the world-wide exclusive rights of LUMC regarding M.tuberculosis latency antigens and expands its collaboration with LUMC into chronic infectious diseases. (November 2005)

  • ISA Pharmaceuticals is awarded a 1.9 M-euro grant from SenterNovem for the development of synthetic long peptides based vaccines against multiple indications. (February 2005)

  • ISA Pharmaceuticals B.V. is founded as a collaborative effort of LUMC and Aglaia Oncology Fund. ISA (Immune System Activating) Pharmaceuticals obtains the world-wide exclusive rights of LUMC regarding the development of vaccines for the treatment of cancer. (November 2004)

  • Scientists at LUMC show for the first time robust anti-tumor activity of a synthetic long peptide against established tumors in a pre-clinical model (2002)

  • Scientists at LUMC obtain first proof of concept of agonistic antibody against CD40 in a pre-clinical tumor model (1998)